Why Global Top‐Tier Teams Choose Chinese Research‐Reagent Brand?. Rigorous validation in metabolism, oncology immunology and gut‐brain‐axis research proves Cloud‐Clone antibodies' global‐competitive ...

Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed ...

A clinical trial called "PARTNERS" is evaluating Infusion of MBP134, a monoclonal antibody cocktail, Infusion of Remdesivir, and Infusion of both, as a treatment for Ebola BDBV infection against ...

As the world marks World Rabies Day 2026 on September 28, the renewed call for awareness comes against the backdrop of a ...

The World Health Organization warned this Monday that the Ebola outbreak in the Democratic Republic of Congo has entered a ...

Summit and AstraZeneca have entered into an agreement whereby AstraZeneca will make an equity investment of $2.0 billion in convertible preferred shares. At the conversion ratio, the investment ...

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.

The gut-brain axis forms a vital signalling network connecting cerebral and intestinal functions, where 5-hydroxytryptamine (5-HT) represents one of the most extensively studied core neurotransmitters ...

AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics and to enter a clinical ...

Kalidi Biotherapeutics is betting that a heavily engineered vaccinia virus can do what CAR-T therapy has largely failed to do: systemically ...

Explore how new cholesterol-lowering therapies, including PCSK9 inhibitors and oral options, are changing the landscape of ...

Vanderbilt Health researchers and colleagues have isolated human monoclonal antibodies from previously infected individuals ...